Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
The goal was to investigate first-in-human safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in people living with HIV on suppressive antiretroviral therapy (ART). As part of the study, baseline (predose) sequence of HIV Gag cell associated RNA isolated from CD4+ cells from the participants was determined.